Arginine depriving enzymes: applications as emerging therapeutics in cancer treatment Neha KumariSaurabh Bansal Review Article 26 July 2021 Pages: 565 - 594
A minimal physiologically based pharmacokinetic model for high-dose methotrexate Giuseppe PesentiMarco FoppoliDavide Manca Original Article Open access 13 June 2021 Pages: 595 - 606
Probenecid increases renal retention and antitumor activity of DFMO in neuroblastoma Chad R. SchultzMatthew A. SwansonAndré S. Bachmann Original Article 15 June 2021 Pages: 607 - 617
Pharmacokinetics of preoperative intraperitoneal 5-FU in patients with pancreatic ductal adenocarcinoma Mikael ÖmanYvonne WettergrenHelena Taflin Original Article Open access 16 June 2021 Pages: 619 - 631
UCP-2 inhibitor enhanced the efficacy of trastuzumab against HER2 positive breast cancer cells Jun HuaZhe ZhangYuan Yuan Original Article Open access 19 June 2021 Pages: 633 - 642
Phase 1 study of safety, pharmacokinetics, and pharmacodynamics of tivantinib in combination with bevacizumab in adult patients with advanced solid tumors William F. MaguireJohn C. SchmitzETCTN-9153 Study Team Original Article 23 June 2021 Pages: 643 - 654
Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase John C. PanettaYiwei LiuMary V. Relling Original Article 25 June 2021 Pages: 655 - 664
The impact of hepatic and renal function on panitumumab exposures in patients with metastatic RAS wild-type colorectal cancer Michael Z. LiaoHans PrenenVijay V. Upreti Original Article Open access 02 July 2021 Pages: 665 - 672
Spatially-resolved pharmacokinetic/pharmacodynamic modelling of bystander effects of a nitrochloromethylbenzindoline hypoxia-activated prodrug Cho Rong HongSunali Y. MehtaKevin O. Hicks Original Article 10 July 2021 Pages: 673 - 687
Targeting cPLA2α inhibits gastric cancer and augments chemotherapy efficacy via suppressing Ras/MEK/ERK and Akt/β-catenin pathways Yingying LiaoWei ChenHuolong Zha Original Article 13 July 2021 Pages: 689 - 697
Prospective clinical trial testing COXEN-based gene expression models of chemosensitivity in dogs with spontaneous osteosarcoma Daniel L. GustafsonKeagan P. CollinsDouglas H. Thamm Original Article 14 July 2021 Pages: 699 - 712
A randomized, single-dose, pharmacokinetic equivalence study comparing MB02 (proposed biosimilar) and reference bevacizumab in healthy Japanese male volunteers Takashi EtoYuji KarasuyamaAna Del Campo García Original Article Open access 16 July 2021 Pages: 713 - 722
Impact of pharmacist consultation at clinical trial inclusion: an effective way to reduce drug–drug interactions with oral targeted therapy Fanny LeenhardtMarie AlexandreWilliam Jacot Original Article 20 July 2021 Pages: 723 - 729
Effect of carboplatin dose capping on survival in recurrent breast, ovary and head and neck cancers: a single institutional retrospective study Pritha RoySatadru BiswasPartha Dasgupta Original Article 23 July 2021 Pages: 731 - 740
Prevalence of drug–drug interactions in sarcoma patients: key role of the pharmacist integration for toxicity risk management Audrey BellesoeurIthar GataaAudrey Thomas-Schoemann Original Article 24 July 2021 Pages: 741 - 751
Correction to: Changes in expression of lysosomal membrane proteins in leucocytes of cancer patients treated with tyrosine kinase inhibitors N. PastvovaJ. HavlasekP. Mlejnek Correction 07 May 2021 Pages: 753 - 753